Compass Therapeutics, Inc. (CMPX)
0.7562
0.00 (0.00%)
USD |
NASDAQ |
Oct 29, 16:00
0.78
+0.02
(+3.15%)
After-Hours: 06:04
Compass Therapeutics Enterprise Value : -34.06M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | -34.06M |
| October 28, 2026 | -33.33M |
| October 27, 2026 | -35.65M |
| October 26, 2026 | -35.68M |
| October 23, 2026 | -33.20M |
| October 22, 2026 | -25.91M |
| October 21, 2026 | -23.56M |
| October 20, 2026 | -20.18M |
| October 19, 2026 | -19.87M |
| October 16, 2026 | -15.37M |
| October 15, 2026 | -8.761M |
| October 14, 2026 | -11.95M |
| October 13, 2026 | -15.91M |
| October 12, 2026 | -1.414M |
| October 09, 2026 | 8.581M |
| October 08, 2026 | 6.852M |
| October 07, 2026 | 13.44M |
| October 06, 2026 | 9.500M |
| October 05, 2026 | 2.746M |
| October 02, 2026 | -15.96M |
| October 01, 2026 | -7.969M |
| September 30, 2026 | 17.05M |
| September 29, 2026 | 27.85M |
| September 28, 2026 | 29.65M |
| September 25, 2026 | 33.25M |
| Date | Value |
|---|---|
| September 24, 2026 | 34.15M |
| September 23, 2026 | 40.46M |
| September 22, 2026 | 53.06M |
| September 21, 2026 | 157.51M |
| September 18, 2026 | 171.92M |
| September 17, 2026 | 162.92M |
| September 16, 2026 | 159.32M |
| September 15, 2026 | 162.92M |
| September 14, 2026 | 182.73M |
| September 11, 2026 | 189.93M |
| September 10, 2026 | 198.93M |
| September 09, 2026 | 222.35M |
| September 08, 2026 | 227.75M |
| September 04, 2026 | 258.36M |
| September 03, 2026 | 256.56M |
| September 02, 2026 | 267.37M |
| September 01, 2026 | 245.76M |
| August 31, 2026 | 260.16M |
| August 28, 2026 | 261.97M |
| August 27, 2026 | 283.58M |
| August 26, 2026 | 267.37M |
| August 25, 2026 | 285.38M |
| August 24, 2026 | 261.97M |
| August 21, 2026 | 261.97M |
| August 20, 2026 | 254.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Viking Therapeutics, Inc. | 2.720B |
| Capricor Therapeutics, Inc. | 238.37M |
| Ardelyx, Inc. | 746.72M |
| Biomea Fusion, Inc. | 10.83M |
| ARS Pharmaceuticals, Inc. | 316.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.15M |
| Total Expenses (Quarterly) | 25.15M |
| EPS Diluted (Quarterly) | -0.1347 |
| Earnings Yield | -53.23% |
| Normalized Earnings Yield | -53.21 |